The following listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended): A compound of Formula I:



I

wherein,

$R^1$ is H,

alkyl having 1 to 5 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, or combinations thereof, and wherein a $-CH_2-$ group can be optionally replaced by -O-, -S-, or -NH-,

cycloalkyl having 3 to 6 carbon atoms, or

cycloalkylalkyl having 4 to 7 carbon atoms; and

$R^2$ is alkyl having 1 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano or combinations thereof, wherein one or more $-CH_2-$ groups is each independently optionally replaced by -O-, -S-, or -NH-, and wherein optionally one or more $-CH_2CH_2-$ groups is replaced in each case by –CH=CH- or -C≡C-,

alkyl ether having 3 to 12 carbon atoms,

cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano or combinations thereof,

cycloalkylalkyl having 4 to 12 carbon atoms, which is unsubstituted or substituted one or more times by $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano, halogen, or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof,

arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, ~~oxo,~~ amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heteroarylalkyl wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heteroaryl portion is unsubstituted or is substituted one or more times ~~in~~ by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, ~~oxo,~~ amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof ;

heterocycle-alkyl wherein the heterocycle portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heterocycle portion is nonaromatic ~~nonarmoatic~~ and is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

carbocycle which is a nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof; and

pharmaceutically acceptable salts thereof,

with the provisos that:

(a) when $R^1$ is substituted or unsubstituted alkyl, ~~methyl~~, then $R^2$ is not substituted or unsubstituted arylalkyl, heteroarylalkyl, 2-(1,2,3,4-tetrahydro)quinolinyl-methyl, or alkyl ~~methyl or 2-butyl~~;

(b) when $R^1$ is cyclopropyl, $R^2$ is not ~~4-methylbenzyl~~ benzyl, methylbenzyl, ethylbenzyl, methylphenethyl, cyclopropylmethyl, or cyclopropylethyl;

~~(c) when $R^1$ is ethyl, then $R^2$ is not ethyl, 3-aminobenzyl, 2-thienylmethyl, 3-thienylmethyl, or 2-pyridylmethyl;~~

~~(d) when $R^1$ is cyclopropyl, then $R^2$ is not cyclopropylmethyl;~~

(c) ~~(e)~~ when $R^1$ is H, then $R^2$ is not alkyl ~~methyl, ethyl, benzyl, 4-methylbenzyl,~~ benzyl, methylbenzyl, phenethyl, or substituted tetrahydrofuranyl; and

(d) ~~(f)~~ when $R^1$ is methoxyethyl, ethoxyethyl, or methoxypropyl, then $R^2$ is not benzyl, 3-dimethylaminobenzyl, or 3-thienylmethyl. [[;]]

~~(g) when $R^1$ is iso-butyl, then $R^2$ is not benzyl; and~~

~~(h) when $R^1$ is n-butyl, then $R^2$ is not n-butyl.~~

2. (Cancelled):

3. (Original): A compound according to claim 1, wherein $R^1$ is alkyl.

4. (Original): A compound according to claim 1, wherein $R^1$ is cycloalkyl.

5. (Original): A compound according to claim 1, wherein $R^1$ is cycloalkylalkyl.

6. (Original): A compound according to claim 1, wherein $R^2$ is alkyl.

7. (Original): A compound according to claim 1, wherein $R^2$ is alkyl ether.

8. (Original): A compound according to claim 1, wherein $R^2$ is cycloalkyl.

9. (Original): A compound according to claim 1, wherein $R^2$ is aryl.

10. (Original): A compound according to claim 1, wherein $R^2$ is arylalkyl.

11. (Original): A compound according to claim 1, wherein $R^2$ is heteroaryl.

12. (Original): A compound according to claim 1, wherein $R^2$ is heteroarylalkyl.

13. (Previously Presented): A compound according to claim 1, wherein $R^2$ is heterocycle.

14. (Previously Presented): A compound according to claim 1, wherein $R^2$ is heterocycle-alkyl.

15. (Previously Presented): A compound according to claim 1, wherein $R^2$ is carbocycle.

16. (Original): A compound according to claim 1, wherein $R^1$ is alkyl, substituted alkyl, cycloalkyl or cycloalkylalkyl.

17. (Currently Amended): A compound according to claim 6, wherein $R^1$ is ~~alkyl,~~ cycloalkyl or cycloalkylalkyl.

18. (Original): A compound according to claim 7, wherein $R^1$ is alkyl, cycloalkyl or cycloalkylalkyl.

19. (Original): A compound according to claim 8, wherein $R^1$ is alkyl,

cycloalkyl or cycloalkylalkyl.

20. (Original): A compound according to claim 9, wherein $R^1$ is alkyl, cycloalkyl or cycloalkylalkyl.

21. (Currently Amended): A compound according to claim 10, wherein $R^1$ is ~~alkyl,~~ cycloalkyl or cycloalkylalkyl.

22. (Original): A compound according to claim 11, wherein $R^1$ is alkyl, cycloalkyl or cycloalkylalkyl.

23. (Currently Amended): A compound according to claim 12, wherein $R^1$ is ~~alkyl,~~ cycloalkyl or cycloalkylalkyl.

24. (Original): A compound according to claim 13, wherein $R^1$ is alkyl, cycloalkyl or cycloalkylalkyl.

25. (Original): A compound according to claim 14, wherein $R^1$ is alkyl, cycloalkyl or cycloalkylalkyl.

26. (Original): A compound according to claim 15, wherein $R^1$ is alkyl, cycloalkyl or cycloalkylalkyl.

27. (Original): A compound according to claim 1, wherein $R^1$ is methyl, ethyl, isopropyl, 2-hydroxyethyl, cyclopropyl, cyclopentyl, or cyclopropylmethyl.

28. (Original): A compound according to claim 1, wherein $R^1$ is methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

29. (Original): A compound according to claim 1, wherein $R^1$ is methyl, ethyl or cyclopropyl.

30. (Original): A compound according to claim 1, wherein $R^2$ is alkyl, arylalkyl, cycloalkyl, aryl, heteroaryl, heteroarylalkyl, or alkyl ether.

31. (Original): A compound according to claim 1, wherein $R^2$ is ethyl, isopropyl, butyl, tert-butyl, cyclopentyl, cyclohexyl, cycloheptyl, or arylalkyl which is unsubstituted or substituted one or more times by F, Cl, CN, $CF_3$, $CH_3$, $C_2H_5$, isopropyl, $OCH_3$, methylenedioxy, ethylenedioxy or combinations thereof.

32. (Original): A compound according to claim 1, wherein $R^2$ is substituted or unsubstituted benzyl, phenethyl or phenpropyl.

33. (Currently Amended): A compound of formula II



II

wherein

$R^{1'}$ is methyl, ethyl, or cyclopropyl; and

$R^{2'}$ is cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$

alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, ~~oxo,~~ amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

carbocycle which is a nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof; and

pharmaceutically acceptable salts thereof.

34. (Currently Amended): A compound of Formula III:



III

wherein

$R^{1''}$ is methyl, ethyl, or cyclopropyl; and

$R^{2''}$ is phenyl,

phenyl which is substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof, or

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, substituted heteroaryl having 5 to 10 ring atoms, in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, $C_{1-4}$-alkyl, $C_{1-4}$-alkoxy, cyano, trifluoromethyl, nitro, ~~oxo,~~ amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino or combinations thereof,

or when $R^1$ is methyl or cyclopropyl $R^2$ can also be cycloalkyl having 3 to 12 carbon atoms; and

pharmaceutically acceptable salts thereof.

35. (Currently Amended): A compound ~~according to claim 1, wherein said compound is~~ selected from:

6-Cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine

~~6-Ethylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine~~

6-Cyclopropylamino-9-(4-fluorobenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2, 6-difluorobenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2, 3-difluorobenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-propyl-2-trifluoromethylpurine

6-Cyclopropylamino-9-cyclopentyl-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3, 4-dimethoxybenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3,4-methylenedioxybenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-thiophenemethyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2-methylphenethyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-cycloheptyl-2-trifluoromethylpurine

6-Methylamino-9-cyclopentyl-2-trifluoromethylpurine

6-Cyclopropylamino-9-cyclohexyl-2-trifluoromethylpurine

6-Methylamino-9-cycloheptyl-2-trifluoromethylpurine

6-Cyclopropylamino-9-cyclopentylmethyl-2-trifluoromethylpurine

6-Cyclopropylamino-9-phenyl-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2-fluorophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-cyclobutyl-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2-norboranane)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(1-indanyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-fluorophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-chlorophenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-thienyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-cyclopentyloxy-4-methoxybenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3, 4-dimethoxyphenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(2, 6-dichloro-4-pyridylmethyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-methoxybenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-cyanophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(2, 4-dimethoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-nitrobenzyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(6-methoxy-3-pyridyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(4-pyridyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-pyridyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(4-dimethylaminophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-aminophenyl)-2-trifluoromethylpurine
6-Methylamino-9-(2, 4-dimethoxy-5-pyrimidyl)-2-trifluoromethylpurine
6-Methylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(3-acetylphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-furanyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(4-ethoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(2-ethoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3, 4-methylenedioxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-ethoxyphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(3,4-dimethoxyphenyl)-2-trifluoromethylpurine; and

pharmaceutically acceptable salts thereof.

36. (Currently Amended): A compound according to claim 35 ~~34~~, wherein said compound is selected from:
6-Cyclopropylamino-9-(2,3-difluorobenzyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-cyclopentyl-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3,4-dimethoxybenzyl)-2-trifluoromethylpurine

6-Cyclopropylamino-9-cycloheptyl-2-trifluoromethylpurine
6-Methylamino-9-cyclopentyl-2-trifluoromethylpurine
6-Cyclopropylamino-9-cyclohexyl-2-trifluoromethylpurine
6-Methylamino-9-cycloheptyl-2-trifluoromethylpurine
6-Cyclopropylamino-9-phenyl-2-trifluoromethylpurine
6-Cyclopropylamino-9-(2-fluorophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-cyclobutyl-2-trifluoromethylpurine
6-Cyclopropylamino-9-(2-norboranane)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(4-fluorophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(4-chlorophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-thienyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3, 4-dimethoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(2, 6-dichloro-4-pyridylmethyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(4-methoxybenzyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-cyanophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-nitrobenzyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(4-pyridyl)-2-trifluoromethylpurine
6-Methylamino-9-(2, 4-dimethoxy-5-pyrimidyl)-2-trifluoromethylpurine
6-Methylamino-9-(4-methoxyphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(3-acetylphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(3-methoxyphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(3-nitrophenyl)-2-trifluoromethylpurine
6-Cyclopropylamino-9-(3-ethoxyphenyl)-2-trifluoromethylpurine
6-Methylamino-9-(3,4-dimethoxyphenyl)-2-trifluoromethylpurine; and

pharmaceutically acceptable salts thereof.

37. (Cancelled):

38. (Cancelled):

39. (Cancelled):

40. (Cancelled):

41. (Cancelled):

42. (Cancelled):

43. (Cancelled):

44. (Cancelled):

45. (Cancelled):

46. (Cancelled):

47. (Cancelled):

48. (Cancelled):

49. (Cancelled):

50. (Cancelled):

51. (Cancelled):

52. (Cancelled):

53. (Cancelled):

54. (Cancelled):

55. (Cancelled):

56. (Cancelled):

57. (Cancelled):

58. (Cancelled):

59. (Cancelled):

60. (Previously Presented): A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

61. (Previously Presented): A composition according to claim 60, wherein said composition contains 0.1-50 mg of said compound.

62. (Cancelled):

63. (Cancelled):

64. (Cancelled):

65. (Cancelled):

66. (Cancelled):

67. (Cancelled):

68. (Currently Amended): A method of treating a patient suffering from an allergic or inflammatory disease, resulting from decreased cyclic AMP levels, elevated phosphodiesterase 4 levels, or both, comprising administering to said patient an effective amount of a compound according to formula $I^c$:




$I^c$

wherein,

$R^{1c}$ is H,

alkyl having 1 to 5 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, or combinations thereof, and wherein a $-CH_2-$ group can be optionally replaced by -O-, -S-, or -NH-,

cycloalkyl having 3 to 6 carbon atoms, or

cycloalkylalkyl having 4 to 7 carbon atoms;

$R^{2c}$ is alkyl having 1 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano or combinations thereof, wherein one or more $-CH_2-$ groups is each independently optionally replaced by -O-, -S-, or -NH-, and wherein optionally one or more $-CH_2CH_2-$ groups is replaced in each

case by –CH=CH- or -C≡C-,

alkyl ether having 3 to 12 carbon atoms,

cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano or combinations thereof,

cycloalkylalkyl having 4 to 12 carbon atoms, which is unsubstituted or substituted one or more times by $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano, halogen, or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof,

arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, $C_{1-4}$

alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, ~~oxo,~~ amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heteroarylalkyl wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heteroaryl portion is unsubstituted or is substituted one or more times in by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, ~~oxo,~~ amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof,

heterocycle-alkyl wherein the heterocycle portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heterocycle portion is nonaromatic ~~nonarmoatic~~ and is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

carbocycle which is a nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times by

halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof; and

pharmaceutically acceptable salts thereof,

wherein when $R^{1c}$ is methyl, then $R^{2c}$ is not arylalkyl, methyl or 2-butyl, and when $R^{1c}$ is H, then $R^{2c}$ is not benzyl, and

with the ~~proviso~~ provisos that:
when $R^{1c}$ is substituted or unsubstituted alkyl, $R^{2c}$ is not substituted or unsubstituted arylalkyl; and
when $R^{1c}$ is H, then $R^{2c}$ is not benzyl, methylbenzyl or phenethyl
~~said compound is not 6-methylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine~~.

69. (Cancelled):

70. (Currently Amended): A method according to claim 68, wherein:
(a) when $R^{1c}$ is methyl, then $R^{2c}$ is not arylalkyl, heteroarylalkyl, 2-(1,2,3,4-tetrahydro)quinolinyl-methyl, methyl or 2-butyl;
(b) when $R^{1c}$ is cyclopropyl, $R^{2c}$ is not 4-methylbenzyl;
(c) when $R^{1c}$ is ethyl, then $R^{2c}$ is not ethyl, 3-aminobenzyl, 2-thienylmethyl, 3-thienylmethyl, or 2-pyridylmethyl;
(d) when $R^{1c}$ is cyclopropyl, then $R^{2c}$ is not cyclopropylmethyl;
(e) when $R^{1c}$ is H, then $R^{2c}$ is not methyl, ethyl, benzyl, ~~4-methylbenzyl,~~ or substituted tetrahydrofuranyl;
(f) when $R^{1c}$ is methoxyethyl, then $R^{2c}$ is not benzyl, 3-dimethylaminobenzyl, or 3-thienylmethyl;
(g) when $R^{1c}$ is iso-butyl, then $R^{2c}$ is not benzyl; and

alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, ~~exo,~~ amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, hydroxamic acid, carboxamide, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

said process comprising:
reacting 6-*N*-$R^1$-9-$CF_3$-substituted ~~6-*N*-$R^1$-substituted~~ adenine with an arylboronic acid or heteroarylboronic acid in the presence of trialkylamine wherein the alkyl portions each have 1 to 5 carbon atoms as a base, a copper catalyst, and a polar aprotic solvent, at a temperature of at least 50°C.

72. (Previously Presented): A compound according to claim 1, wherein $R^2$ is cycloalkylalkyl.

73. (Previously Presented): A compound according to claim 72 wherein $R^1$ is alkyl, cycloalkyl or cycloalkylalkyl.

74. (Previously Presented): A compound according to claim 1, wherein said compound is 6-cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof.

75. (Currently Amended): A method according to claim 68 ~~54~~, wherein said compound is 6-cyclopropylamino-9-(2-methoxyphenyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof.

76. (Cancelled):

77. (Previously Presented): A compound according to claim 1, wherein said compound is 6-cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof

(h) when $R^{1c}$ is n-butyl, then $R^{2c}$ is not n-butyl.

71. (Currently Amended): A process for preparing compounds of the formula IV



IV

wherein

$R^1$ is H,

alkyl having 1 to 5 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, or combinations thereof, and wherein a $-CH_2-$ group can be optionally replaced by -O-, -S-, or -NH-,

cycloalkyl having 3 to 6 carbon atoms, or

cycloalkylalkyl having 4 to 7 carbon atoms; and

$R^2$ is aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, hydroxamic acid, carboxamide, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, $C_{1-4}$

78. (Currently Amended): A method according to claim 68 ~~54~~, wherein said compound is 6-cyclopropylamino-9-(2-fluorobenzyl)-2-trifluoromethylpurine, or a pharmaceutically acceptable salt thereof.

79. (Cancelled):

80. (Previously Presented): A compound according to claim 1, wherein $R^1$ is alkyl or cycloalkyl and $R^2$ is phenyl or heteroaryl, in each case substituted or unsubstituted.

81. (Currently Amended): A method according to claim 68 ~~54~~, wherein $R^1$ is alkyl or cycloalkyl and $R^2$ is phenyl or heteroaryl, in each case substituted or unsubstituted.

82. (Cancelled):

83. (New): A method of claim 68, wherein the patient is suffering from chronic obstructive pulmonary disease or asthma.

84. (New): A method according to claim 68, wherein said disease state is asthma, chronic bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic contact eczema, allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and wide-area pyodermias, endogenous acne, exogenous acne,

acne rosacea, Beghet's disease, anaphylactoid purpura nephritis, an inflammatory bowel disease, leukemia, multiple sclerosis, a gastrointestinal disease, or an autoimmune disease.

85. (New): A method of treating a patient suffering from an allergic or inflammatory disease associated with decreased cyclic AMP levels, elevated phosphodiesterase 4 levels, or both, said method comprising administering to said patient an anti-inflammatory effective amount of a compound according to claim 33.

86. (New): A method of claim 85, wherein the patient is suffering from chronic obstructive pulmonary disease or asthma.

87. (New): A method according to claim 85, wherein said disease state is asthma, chronic bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic contact eczema, allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and wide-area pyodermias, endogenous acne, exogenous acne, acne rosacea, Beghet's disease, anaphylactoid purpura nephritis, an inflammatory bowel disease, leukemia, multiple sclerosis, a gastrointestinal disease, or an autoimmune disease.

88. (New): A method of treating a patient suffering from an allergic or inflammatory disease associated with decreased cyclic AMP levels, elevated phosphodiesterase 4 levels, or both, said method comprising administering to said patient

an anti-inflammatory effective amount of a compound according to claim 34.

89. (New): A method of claim 88, wherein the patient is suffering from chronic obstructive pulmonary disease or asthma.

90. (New): A method according to claim 88, wherein said disease state is asthma, chronic bronchitis, chronic obstructive pulmonary disease, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic contact eczema, allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and wide-area pyodermias, endogenous acne, exogenous acne, acne rosacea, Beghet's disease, anaphylactoid purpura nephritis, an inflammatory bowel disease, leukemia, multiple sclerosis, a gastrointestinal disease, or an autoimmune disease.

91. (New): A method of treating a patient suffering from an allergic or inflammatory disease associated with decreased cyclic AMP levels, elevated phosphodiesterase 4 levels, or both, said method comprising administering to said patient an anti-inflammatory effective amount of a compound according to claim 35.

92. (New): A method of claim 91, wherein the patient is suffering from chronic obstructive pulmonary disease or asthma.

93. (New): A method according to claim 91, wherein said disease state is asthma, chronic bronchitis, chronic obstructive pulmonary disease, atopic dermatitis,

urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, esoniophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock, adult respiratory distress syndrome, cystic fibrosis, arterial restenosis, artherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, pyresis, diabetes mellitus, pneumoconiosis, chronic obstructive airways disease, chronic obstructive pulmonary disease, toxic contact eczema, allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, sunburn, pruritis in the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and wide-area pyodermias, endogenous acne, exogenous acne, acne rosacea, Beghet's disease, anaphylactoid purpura nephritis, an inflammatory bowel disease, leukemia, multiple sclerosis, a gastrointestinal disease, or an autoimmune disease.

94. (New): A compound according to claim 1, wherein

$R^2$ is alkyl having 1 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano or combinations thereof, wherein one or more $-CH_2-$ groups is each independently optionally replaced by -O-, -S-, or -NH-, and wherein optionally one or more $-CH_2CH_2-$ groups is replaced in each case by –CH=CH- or -C≡C-,

alkoxyalkyl having 3 to 12 carbon atoms,

cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano or combinations thereof,

cycloalkylalkyl having 4 to 12 carbon atoms, which is unsubstituted or substituted one or more times by $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano, halogen, or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$-alkanoyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof,

arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$- alkanoyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heteroarylalkyl wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heteroaryl portion is unsubstituted or is substituted one or more times ~~in~~ by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times by halogen,

aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof;

heterocycle-alkyl wherein the heterocycle portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heterocycle portion is nonaromatic and is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

carbocycle which is a nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$-alkanoyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof.

95. (New): A compound according to claim 33, wherein

$R^{2'}$ is cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$-alkanoyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-}$

$_4$-alkylsulphonyl, phenoxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

carbocycle which is a nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$-alkanoyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof.

96. (New): A compound according to claim 34, wherein

$R^{2''}$ is phenyl,

phenyl which is substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$-alkanoyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-

alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof, or

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, substituted heteroaryl having 5 to 10 ring atoms, in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, aryl, $C_{1-4}$-alkyl, $C_{1-4}$-alkoxy, cyano, trifluoromethyl, nitro, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino or combinations thereof.

97. (New): A compound according to claim 1, wherein

$R^1$ is cyclopropyl; and

$R^2$ is alkyl having 1 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, hydroxy, cyano or combinations thereof, wherein one or more $-CH_2-$ groups is each independently optionally replaced by -O-, -S-, or -NH-, and wherein optionally one or more $-CH_2CH_2-$ groups is replaced in each case by –CH=CH- or -C≡C-,

cycloalkyl having 3 to 12 carbon atoms, which is unsubstituted or substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano or combinations thereof,

cycloalkylalkyl having 4 to 12 carbon atoms, which is unsubstituted or substituted one or more times by $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, cyano, halogen, or combinations thereof,

aryl having 6 to 14 carbon atoms, which is unsubstituted or substituted one or more times by halogen, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, or combinations thereof,

arylalkyl having 7 to 16 carbon atoms, which is unsubstituted or substituted one

or more times by halogen, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, or combinations thereof,

heteroaryl having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or substituted one or more times by halogen, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heteroarylalkyl wherein the heteroaryl portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heteroaryl portion is unsubstituted or is substituted one or more times ~~in~~ by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl,or combinations thereof,

heterocycle having 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom, which is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof ;

heterocycle-alkyl wherein the heterocycle portion has 5 to 10 ring atoms in which at least 1 ring atom is a heteroatom and the alkyl portion has 1 to 3 carbon atoms, the heterocycle portion is nonaromatic and is unsubstituted or is substituted one or more times by halogen, aryl, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, cyano, trifluoromethyl, nitro, oxo, amino, $C_{1-4}$-alkylamino, di-$C_{1-4}$-alkylamino, carboxy, alkoxycarbonyl, or combinations thereof, or

carbocycle which is a nonaromatic, monocyclic or bicyclic, group having 5 to 14 carbon atoms, which is unsubstituted or is substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, halogenated $C_{1-4}$ alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$-alkanoyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof.

98. (New): A method according to claim 68, wherein
(a) when $R^1$ is substituted or unsubstituted alkyl, then $R^2$ is not substituted or unsubstituted arylalkyl, heteroarylalkyl, 2-(1,2,3,4-tetrahydro)quinolinyl-methyl, or alkyl;
(b) when $R^1$ is cyclopropyl, $R^2$ is not benzyl, methylbenzyl, ethylbenzyl, methylphenethyl, cyclopropylmethyl, or cyclopropylethyl;
(c) when $R^1$ is H, then $R^2$ is not alkyl, benzyl, methylbenzyl, phenethyl, or substituted tetrahydrofuranyl; and
(d)when $R^1$ is methoxyethyl, ethoxyethyl, or methoxypropyl, then $R^2$ is not benzyl, 3-dimethylaminobenzyl, or 3-thienylmethyl.

99. (New): A compound according to claim 34, wherein
$R^{2''}$ is phenyl, or

phenyl which is substituted one or more times by halogen, $C_{1-4}$ alkyl, halogenated $C_{1-4}$ alkyl, hydroxy, $C_{1-4}$-alkoxy, nitro, methylenedioxy, ethylenedioxy, amino, $C_{1-4}$ alkylamino, di-$C_{1-4}$-alkylamino, $C_{1-4}$-hydroxyalkyl, $C_{1-4}$-hydroxyalkoxy, carboxy, cyano, $C_{2-4}$-acyl, $C_{2-4}$-alkoxycarbonyl, $C_{1-4}$-alkylthio, $C_{1-4}$-alkylsulphinyl, $C_{1-4}$-alkylsulphonyl, phenoxy, or combinations thereof.